Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lm-GUCY2C
- Development stage
- Phase 1
- Lead developer
- Thomas Jefferson University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
Lm-GUCY2C is an investigational cancer vaccine consisting of a live-attenuated strain of *Listeria monocytogenes* (Lm) engineered to express the human tumor-associated antigen guanylyl cyclase C (GUCY2C). Developed by researchers at Thomas Jefferson University, the vaccine leverages the natural ability of *Listeria* to enter antigen-presenting cells and stimulate a potent CD8+ T-cell response against cells expressing the target antigen. GUCY2C is a membrane-bound cyclase normally restricted to the apical surface of intestinal epithelial cells but is frequently overexpressed in colorectal and small bowel adenocarcinomas, making it a viable target for immunotherapy. In clinical settings, Lm-GUCY2C is typically evaluated as a booster component in a heterologous prime-boost vaccination strategy, following a priming dose with an adenoviral vector (Ad5.F35-hGUCY2C-PADRE), to maximize the induction of tumor-specific immunity in patients with advanced gastrointestinal cancers.
- Other names
- Listeria monocytogenes-GUCY2C vaccinerecombinant Listeria monocytogenes-GUCY2C
02
Targets
GUCY2C (Guanylate cyclase C receptor)
Beyond the preview
Go deeper on Lm-GUCY2C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lm-GUCY2C.